Deerfield Management Company, L.P. (Series C) Mirati Therapeutics, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$4.84 Billion
Q1 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$39.16 - $88.71 $10.6 Million - $24 Million	-270,000 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$75.82 - $150.97 $13.8 Million - $27.5 Million	182,000 Added 206.82%	270,000 $22.2 Million
Q4 2021 Feb 14, 2022	BUY	$132.01 - $190.29 $11.6 Million - $16.7 Million	88,000 New	88,000 $12.9 Million
Q3 2020 Nov 16, 2020	SELL	$113.26 - $167.27 $20.4 Million - $30.1 Million	-179,885 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$72.01 - $120.39 $4.49 Million - $7.5 Million	-62,315 Reduced 25.73%	179,885 $20.5 Million

Q1 2020 May 15, 2020	BUY	$69.78 - $116.21 $4.76 Million - $7.93 Million	68,200 Added 39.2%	242,200 $18.6 Million
Q4 2019 Feb 14, 2020	SELL	$70.76 - $128.86 $4.17 Million - $7.6 Million	-59,000 Reduced 25.32%	174,000 $22.4 Million
Q3 2019 Nov 14, 2019	SELL	$77.91 - $109.6 $2.46 Million - $3.46 Million	-31,600 Reduced 11.94%	233,000 $18.2 Million
Q2 2019 Aug 14, 2019	BUY	$59.49 - $104.71 $737,676 - $1.3 Million	12,400 Added 4.92%	264,600 $27.3 Million
Q1 2019 May 15, 2019	SELL	$43.65 - $78.95 $27.2 Million - $49.1 Million	-622,286 Reduced 71.16%	252,200 $18.5 Million
Q4 2018 Feb 14, 2019	BUY	$32.0 - $47.43 $1.07 Million - $1.59 Million	33,575 Added 3.99%	874,486 $37.1 Million
Q3 2018 Nov 14, 2018	SELL	$47.1 - $62.7 $21.6 Million - $28.8 Million	-459,454 Reduced 35.33%	840,911 $39.6 Million
Q2 2018 Aug 14, 2018	BUY	$26.05 - $52.4 $28.7 Million - $57.8 Million	1,103,365 Added 560.08%	1,300,365 $64.1 Million
Q1 2018 May 15, 2018	SELL	$17.2 - $34.95 $3.06 Million - $6.22 Million	-178,000 Reduced 47.47%	197,000 $6.05 Million
Q4 2017 Feb 14, 2018	BUY	$12.65 - $19.0 $4.74 Million - $7.13 Million	375,000	375,000 $6.84 Million

Others Institutions Holding MRTX

# of Institutions

Shares Held

3.57M

Call Options Held

Put Options Held

36.6K

View Full List

About Mirati Therapeutics, Inc.

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

More about MRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account